VectivBio to Present at the 2022 Jefferies London Healthcare Conference

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022. A live webcast can be accessed through the link below.

Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Presentation Time: 8:35 a.m. GMT / 3:35 a.m. ET
Webcast: https://wsw.com/webcast/jeff255/vect/1857438

An archived webcast of the presentation can be accessed through the Events and Presentations section of VectivBio’s website at www.vectivbio.com.

About VectivBio AG

VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (“CoA”). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

VectivBio Contact:
Patrick Malloy
VectivBio SVP, Investor Relations and Strategic Communications
Patrick.malloy@vectivbio.com

Staff

Recent Posts

Methodist Le Bonheur Healthcare named among Best in Cancer Care by Money magazine

MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…

2 days ago

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…

2 days ago

KORE Helps mCare Digital Launch the Next Generation of Personal Emergency Technology

mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…

2 days ago

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…

2 days ago

Hitachi’s Holography Electron Microscope Attains Unprecedented Resolution

Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…

2 days ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…

2 days ago